Kopran has informed the Board of Directors of the Company at their meeting held today, have considered and approved the Audited Financial Results of the Company for the financial year ended 31st March, 2021. In this regard, the company submitted the following information: Audited Consolidated and Standalone Financial Results for the quarter and financial year ended 31st March, 2021. It has declared that the aforesaid Audit Reports are with unmodified opinion as annexed, Consolidated and Standalone Statement of Assets and Liabilities as at 31st March, 2021, Consolidated and Standalone Cash Flow Statement for the financial year ended 31st March, 2021, Independent Auditor's Report (Consolidated and Standalone) from Khandelwal Jain & Co., Chartered Accountants (Firm Registration No.: 105049W) in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, The Board has recommended a Final dividend of Rs 1.50 (15%) per equity share of Rs 10 each for the year ended 31st March 2021 subject to approval of members at the 62nd AGM. Earlier an interim dividend of Rs 1.50 (15%) per equity share was paid in the month of November, 2020 and Appointment of Pushpendra Pratap Singh & Associates, Company Secretaries as the secretarial Auditors of the Company for the FY 2020-21. Brief Profile of Pushpendra Pratap Singh & Associates is as annexed. The Meeting of the Board of Directors of the Company commenced at 11.30 am and concluded at 13.25 pm.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: